Your email has been successfully added to our mailing list.

×
0 0 0 -0.0040860215053763 0.00623655913978493 0.00749462365591401 0.00688172043010753 0.00731182795698932
Stock impact report

Arrowhead Pharmaceuticals GAAP EPS of -$0.01 in-line, revenue of $829.45M beats by $72.01M [Seeking Alpha]

Arrowhead Pharmaceuticals, Inc. (ARWR) 
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arrowheadpharma.com/investor-relations
Company Research Source: Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome - Slideshow Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway Arrowhead Pharmaceuticals FQ4 2025 Earnings Preview Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics Show less Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
ARWR alerts

from News Quantified
Opt-in for
ARWR alerts

from News Quantified